safety and immunogenicity following recombinant hepatitis b (bio farma) vaccine in adults & children

Conditions: Hepatitis B

Summary: this trial is an experimental, randomized, double blind, prospective intervention study approximately 100 subjects will be enrolled in this trial, divided into 2 arms, as follow: for adult (18-40 years old)

each study age group/arm will be divided into two groups of treatment. one group will receive investigational product and one other group will receive active comparator. this study is sequential age de-escalation. to be conducted in heathy adults (18-40 years old) and followed by children (10-17 years old) ). before the study started, the subjects will be assessed for anti hbs antibody. for subjects with anti-hbs not protective (\< 10miu/ml) before immunization, additional 2 doses will be required with 1 month interval.

Eligibility criteria:
inclusion criteria: adult 1. healthy individu as determined by clinical judgment, including a medical history, physical exam, rontgen thorax and laboratory results, which confirms the absence of a current or past disease state considered significant by the investigator. 2. subjects have been informed properly regarding the study and signed the informed consent form 3. subjects will commit to comply with the instructions of the investigator and the schedule of the trial children: 1. healthy individu as determined by clinical judgment, including a medical history, physical exam and rontgen thorax which confirms the absence of a current or past disease state considered significant by the investigator. 2. subjects/parents/guardian(s) have been informed properly regarding the study and signed the informed consent form and 3. subject/parents/guardian(s) will commit to comply with the instructions of the investigator and the schedule of the trial. exclusion criteria: 1. subject concomitantly enrolled or scheduled to be enrolled in another trial 2. any direct relatives relationship with the study team. 3. evolving mild, moderate or severe illness, especially infectious diseases or fever (axillary temperature ³ 37.5°c) within the 48 hours preceding enrollment. 4. known history of allergy to any component of the vaccines (based on anamnesis) 5. known history of immunodeficiency disorder (hiv infection, leukemia, lymphoma, or malignancy) 6. history of uncontrolled coagulopathy or blood disorders contraindicating for phlebotomy. 7. subject who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products, or corticosteroid therapy and other immunosuppresant). 8. any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives. 9. pregnancy or planning a pregnancy within the next 3 months \& lactation. (for adults) 10. subject already immunized with any vaccine within 4 weeks prior and expects to receive other vaccines within 4 weeks following immunization. 11. hbsag positive 12. subjects with known history of hepatitis b infection. 13. subjects who have received hepatitis b vaccination which proven by vaccination records. 14. subject planning to move from the study area before the end of study period.

Keywords: vaccine hepatitis b infection virus